Subaward Agreement
Exhibit 10.15
Non-Federal
| Subaward Agreement | |||
| Prime Awardee | Subawardee | ||
| Institution/Organization (“PRIME RECIPIENT”) | Institution/Organization (“SUBRECIPIENT”) | ||
| Name: | Shuttle Pharmaceutical, LLC | Name: | Rhode Island Hospital |
| Address: | 0 Xxxxxxxx Xxxxx, Xxxxx 000 Xxxxxxxxx, XX 00000 |
Address: | 000 Xxxx Xxxxxx Xxxxxxxxxx, XX 00000 |
Prime Award No. HHSN261201400013C |
Subaward No. | ||
Sponsor National Cancer Institute |
| |
Subaward Period of Performance Phase 110/27/14 - 6/18/15 Phase II 6/19/15- 6/18/17 |
Amount Funded this Action $65,549 |
Est. Total (if incrementally funded) $688,818 |
Project Title Development of Radiation Modulators for Use DurinQ Radiotherapy |
| |
| Reporting Requirements [Check here if applicable: 181 See Attachment 4] | ||
Terms and Conditions
1) Prime Recipient hereby awards a cost reimbursable subaward, as described above, to Subrecipient. The statement of work and budget for this subaward are (check one): _____ as specified in Subrecipient’s proposal dated _______________; or _X_ as shown in Attachments 3 & 4. In its performance of subaward work, Subrecipient shall be an independent entity and not an employee or agent of Prime Recipient.
2) Prime Recipient shall reimburse Subrecipient not more often than monthly for allowable costs. All invoices shall be submitted using Subrecipient’s standard invoice, but at a minimum shall include current and cumulative costs (including cost sharing), subaward number, and certification as to truth and accuracy of invoice. Invoices that do not reference Prime Recipient’s subaward number shall be returned to Subrecipient. Invoices and questions concerning invoice receipt or payments should be directed to the appropriate party’s Financial Contact, as shown in Attachment 2.
3) A final statement of cumulative costs incurred, including cost sharing, marked “FINAL,” must be submitted to Prime Recipient’s Administrative Contact NOT LATER THAN sixty (60) days after subaward end date. The final statement of costs shall constitute Subrecipient’s final financial report.
4) All payments shall be considered provisional and subject to adjustment within the total estimated cost in the event such adjustment is necessary as a result of an adverse audit finding against the Subrecipient.
5) Matters concerning the technical performance of this subaward should be directed to the appropriate party’s Project Director, as shown in Attachment 2. Technical reports are required as shown above, “Reporting Requirements.”
6) Matters concerning the request or negotiation of any changes in the terms, conditions, or amounts cited in this subaward agreement should be directed to the appropriate party’s Administrative Contact, as shown in Attachment 2. Any such changes made to this subaward agreement require the written approval of each party’s Authorized Official, as shown in Attachment 2.
7) Each party shall be responsible for its negligent acts or omissions and the negligent acts or omissions of its employees, officers or directors, to the extent allowed by law.
8) Either party may terminate this agreement with thirty days written notice to the appropriate party’s Administrative Contact, as shown in Attachment 2. Prime Recipient shall pay Subrecipient for all allowable, noncancellable obligations in the event of termination.
9) No-cost extensions require the approval of the Prime Recipient. Any requests for a no-cost extension should be addressed to and received by the Administrative Contact, as shown in Attachment 2, not less than thirty days prior to the desired effective date of the requested change.
10) The Subaward is subject to the terms and conditions of the Prime Award and other special terms and conditions, as identified in Attachment 1.
| By an Authorized Official of PRIME RECIPIENT: | By an Authorized Official of SUBRECIPIENT: |
Xxxxxxx Xxxxxxxxxx, MD - CEO Date |
 |
Non-Federal
Attachment 2 Subaward Ar._ reement | |||
| Prime Recipient Contacts | Subrecipient Contacts | ||
| Administrative Contact | Administrative Contact | ||
| Name: | Xxxxx X. Xxxxxxxxxx President & CFO |
Name: | Xxx-Xxxxx Xxxxxxxx |
| Address: | Shuttle Pharmaceuticals, LLC Xxx Xxxxxxxx Xxxxx, Xxxxx 000 Xxxxxxxxx, XX 00000-0000 |
Address: | Office of Research Administration 0 Xxxxxx Xxxxxx, Xxxxx 0.000 Xxxxxxxxxx, XX 00000-0000 |
| Telephone: | 000-000-0000 | Telephone: | 000.000.0000 |
| Fax: | 000-000-0000 | Fax: | 000.000.0000 |
| Email: | xxxx00@xxx.xxx | Email: | xxxxxxxxx@Xxxxxxxx.xxx |
| Principal Investigator | Project Director | ||
| Name: | Xxxxxxxx Xxxxxxxx, MD | Name: | Xxxxxxx Xxxxxxxx, MD |
| Address: | Shuttle Pharmaceuticals, LLC Xxx Xxxxxxxx Xxxxx, Xxxxx 000 Xxxxxxxxx, XX 00000-0000 |
Address: | Rhode Island Hospital 000 Xxxx Xxxxxx, XXX 0 Xxxxxxxxxx, XX 00000 |
| Telephone: | 000-000-0000 | Telephone: | 000.000.0000 |
| Fax: | 000-000-0000 | Fax: | 000.000.0000 |
| Email: | xxxxx00@xxx.xxx | Email: | xxxxxxxxx@xxxxxxxx.xxx |
| Financial Contact | Financial Contact | ||
| Name: | Xxxxx X. Xxxxxxxxxx President & CFO President & CFO |
Name: | Xxxxxx Xxxx Manager, Research Finance |
| Address: | Shuttle Pharmaceuticals, LLC Xxx Xxxxxxxx Xxxxx, Xxxxx 000 Xxxxxxxxx, XX 00000-0000 |
Address: | Rhode Island Hospital 0 Xxxxxx Xxxxxx, Xxxxx 0.000 Xxxxxxxxxx, XX 00000-0000 |
| Telephone: | 000-000-0000 | Telephone: | 000-000-0000 |
| Fax: | 000-000-0000 | Fax: | 000-000-0000 |
| Email: | xxxx00@xxx.xxx | Email: | xxxxx@xxxxxxxx.xxx |
| Authorized Official | Authorized Official | ||
| Name: | Xxxxxxx Xxxxxxxxxx, MD CEO |
Name: | Xxxx X. Xxxxx Administrative Manager |
| Address: | Shuttle Pharmaceuticals, LLC Xxx Xxxxxxxx Xxxxx, Xxxxx 000 Xxxxxxxxx, XX 00000-0000 |
Address: | Rhode Island Hospital Office of Research Administration 0 Xxxxxx Xxxxxx, Xxxxx 0.000 Xxxxxxxxxx, XX 00000-0000 |
| Telephone: | 000-000-0000 | Telephone: | 000.000.0000 |
| Fax: | 000-000-0000 | Fax: | 000.000.0000 |
| Email: | xxxxxxxx@xxxxxxxxxx.xxx | Email: | xxxxxx@xxxxxxxx.xxx |
